Luxempart S.A.: Luxempart acquires 14.9% of Medios AG and becomes a new
anchor shareholder and long-term partner for the company

   EQS-News: Charles Barker Corporate Communications GmbH / Key
   word(s): Investment
   Luxempart S.A.: Luxempart acquires 14.9% of Medios AG and becomes
   a new anchor shareholder and long-term partner for the company
   20.06.2024 / 09:06 CET/CEST
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   
   Luxembourg, June 20, 2024

   Luxempart is delighted to announce its strategic investment in
   Medios AG, a leading publicly listed specialty pharma platform in
   Europe. Luxempart has acquired a 14.9% stake from Manfred
   Schneider, the founder of Medios AG. This transaction resolves
   the shareholding succession of Manfred Schneider and establishes
   Luxempart as a new anchor shareholder.

   "I sought an investor to take over my holdings in Medios, and I'm
   pleased to have reached an agreement with Luxempart. Their
   thorough analysis and deep understanding of Medios and its
   strategy, combined with their long-term commitment and support
   from entrepreneurial families, convinced me they are the right
   partner for Medios' future," expresses Manfred Schneider, founder
   of Medios on the transaction.

   Medios AG is a pan-European platform focusing on specialty
   pharmaceuticals for chronic and/or rare diseases. The business
   activities are centered around wholesale of such drugs and the
   compounding and supply of patient-specific therapies. These
   therapies are particularly targeted at six focus indication
   areas: oncology, neurology, autoimmune diseases, ophthalmology,
   infectious diseases and haemophilia. With the recent acquisition
   of Ceban Pharmaceuticals in the Netherlands, Medios has
   diversified its business operations both regionally and in terms
   of business activities. This strategic acquisition not only
   offers numerous synergies, but also aligns with Medios' vision to
   become the leading European specialty pharma platform.

   "We have been monitoring the company for several years and are
   impressed by the company's strategy execution and progress over
   this time period", says John Penning, Managing Director at
   Luxempart.

   Luxempart is excited to support the management and the employees
   of Medios AG on their successful journey with our expertise and
   capabilities to achieve their strategic and financial goals. We
   have met a strong and committed team and we look forward to
   supporting them by all means in this new growth phase of Medios.
   Next to continuous operational improvements and the successful
   integration of Ceban, we see further M&A as a key lever to
   generate shareholder value going forward.

   Florian Herger, Principal at Luxempart, emphasizes: "We are
   convinced of Medios' capabilities and its strong management team
   to continue excelling in this attractive market. We are excited
   to bring our expertise to the table, supporting the Medios team
   to reach its strategic and financial goals through value
   enhancing growth."

   Rudolf Ohnesorge, Member of the Group Executive Committee and
   responsible for the DACH activities of Luxempart, complements:
   "This transaction fits well with our strategy to take significant
   positions in market leading companies as an active owner and
   partner to the management team. We feel well positioned to
   accompany Medios on their ambitious journey especially when it
   comes to further internationalization."

About Luxempart

   Luxempart is a Luxembourg-based listed investment company with a
   net worth of EUR 2.3bn backed by Luxembourgish entrepreneurial
   families. With permanent capital and a professional investment
   team, Luxempart provides flexible long-term financing solutions
   to entrepreneurs, families and management and actively supports
   its portfolio companies in their growth and international
   expansion. Luxempart's Direct Investment strategy consists in
   investing equity tickets ranging from EUR 25m up to EUR 100m in
   the DACH region, France, BeLux and Northern Italy.

   Contact: John Penning +352 437 43 5117
   www.luxempart.lu

____________________________________________________________

   20.06.2024 CET/CEST Dissemination of a Corporate News,
   transmitted by EQS News - a service of EQS Group AG.
   The issuer is solely responsible for the content of this
   announcement.
   The EQS Distribution Services include Regulatory Announcements,
   Financial/Corporate News and Press Releases.
   Archive at www.eqs-news.com
     ____________________________________________________________

1929343 20.06.2024 CET/CEST